AMT-253 / Suzhou Maximum Bio-tech - LARVOL DELTA

Antibody-Drug Conjugates in the Pipeline for Treatment of Melanoma: Target and Pharmacokinetic Considerations. (PubMed, Drugs R D) - "So far, the antibody-drug conjugates have struggled from efficacy problems, with modest effects at best, leading many to be discontinued for melanoma. At the same time, conjugates such as AMT-253, targeting melanoma cell adhesion molecule, and mecbotamab vedotin  targeting AXL receptor tyrosine kinase, are among the most exciting for melanoma treatment in the future."

Journal • PK/PD data • Review • Genetic Disorders • Melanoma • Oncology • Skin Cancer • Solid Tumor • AXL • MCAM

AMT-253, a first-in-class MUC18-targeting antibody-drug conjugate, for the treatment of MUC18-positive solid tumors (AACR 2024) - P1 | "Taken together, our preclinical in vivo efficacy and toxicity studies demonstrated that AMT-253 has a wide therapeutic window and could potentially provide benefits for cancer patients with highly unmet medical needs. AMT-253 is currently being evaluated in a Phase I first-in-human clinical trial (NCT05906862)."

Cervical Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Melanoma • Oncology • Osteosarcoma • Ovarian Cancer • Sarcoma • Solid Tumor • MCAM

AMT-253 in Patients With Advanced Solid Tumours (clinicaltrials.gov) - P1/2 | N=96 | Recruiting | Sponsor: Multitude Therapeutics Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Melanoma • Oncology • Solid Tumor

AMT-253 in Patients With Advanced Solid Tumours (clinicaltrials.gov) - P1/2 | N=96 | Not yet recruiting | Sponsor: Multitude Therapeutics Inc.

Metastases • New P1/2 trial • Melanoma • Oncology • Solid Tumor

A cell surface-binding antibody atlas nominates a MUC18-directed antibody-drug conjugate for targeting melanoma. (PubMed, Cancer Res) - "AMT-253, an MUC18-directed ADC based on topoisomerase I inhibitor exatecan and a self-immolative T moiety, had a higher therapeutic index compared with its microtubule inhibitor-based counterpart and favorable pharmacokinetics and tolerability in monkeys...Beyond melanoma, AMT-253 was also efficacious in a wide range of MUC18-expressing solid tumors. Efficient target/antibody discovery in combination with the T moiety-exatecan linker-payload exemplified here may facilitate discovery of new ADC to improve cancer treatment."

Journal • Melanoma • Mucosal Melanoma • Oncology • Solid Tumor • ASAP1 • MCAM

AMT-253 in Patients With Selected Advanced Solid Tumours (clinicaltrials.gov) - P1 | N=54 | Recruiting | Sponsor: Multitude Therapeutics (Australia) Pty Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

AMT-253 in Patients With Selected Advanced Solid Tumours (clinicaltrials.gov) - P1 | N=54 | Not yet recruiting | Sponsor: Multitude Therapeutics (Australia) Pty Ltd

Metastases • New P1 trial • Oncology • Solid Tumor